IL2 and neoplasm: As a therapy, mice were either treated with immunotherapy in the form of repeated anti-PD-L1 antibody injections every third day, starting at tumor implantation, or chemo-immunotherapy in the form of single doxorubicin injection followed by daily administration of highly dosed IL-2 starting on day 8 after tumor implantation.